Boehringer announces IPF deal with Korea's Bridge Biotherape...

Boehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for idiopathic pulmonary fibrosis (IPF).

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failu...

Boehringer adds to obesity alliance with Denmark’s Gubra

Two years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a higher level.

Boehringer looks to enhance COPD care with new registry

Boehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience in COPD), to better understan

AbbVie gets crucial US approval for psoriasis drug Skyrizi

With one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Skyrizi approved in the US.

BI chief "regrets" Brexit, but continues to invest in UK

The head of Germany’s Boehringer Ingelheim has said that he “regrets” Brexit, but reassured patients in the country that the company still regards it as an important market for new drug lau